TRIM24/BRPF1-IN-2

CAS No. 3033288-68-2

TRIM24/BRPF1-IN-2( —— )

Catalog No. M36595 CAS No. 3033288-68-2

TRIM24/BRPF1-IN-2 is a selective dual TRIM24/BRPF1 inhibitor with anticancer activity that inhibits proliferation, gene and protein expression, and colony formation of prostate cancer cells in a dose-dependent manner.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 922 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    TRIM24/BRPF1-IN-2
  • Note
    Research use only, not for human use.
  • Brief Description
    TRIM24/BRPF1-IN-2 is a selective dual TRIM24/BRPF1 inhibitor with anticancer activity that inhibits proliferation, gene and protein expression, and colony formation of prostate cancer cells in a dose-dependent manner.
  • Description
    TRIM24/BRPF1-IN-2 is a selective dual TRIM24/BRPF1 inhibitor with anticancer activity that inhibits proliferation, gene and protein expression, and colony formation of prostate cancer cells in a dose-dependent manner.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Epigenetic Reader Domain
  • Recptor
    Epigenetic Reader Domain
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    3033288-68-2
  • Formula Weight
    386.47
  • Molecular Formula
    C20H22N2O4S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(N1C2=CC=C(C=C2CC1)NS(=O)(=O)C3=CC(=CC=C3OC)C4CC4)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • GSK620

    GSK620 is a pan-BD2 inhibitor, which shows an anti-inflammatory phenotype in human whole blood with excellent broad selectivity, developability, and in vivo oral pharmacokinetics.

  • AW68

    AW68 is a potential small molecule BRD4 inhibitor that prevents and treats BRD4-related diseases and can be used in cancer research.

  • JQAD1

    JQAD1 is a potent and selective histone acetyltransferase EP300 degrader (PROTAC?; DC50≤ 31.6 nM); comprises an EP300 inhibitor, A485, joined by a linker to a cereblon E3 ligase ligand.